TACR1 and neoplasm: Altogether, data show that NK-1R is a new therapeutic target for the treatment of HB because NK-1R antagonists (e.g., aprepitant) exert an antitumor effect (antiproliferative, apoptosis, tumor volume is decreased) against HB cells (they overexpress the NK-1R (truncated form) and the receptor must be used as a tumor marker).